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Original Article
Elevated Serum Macrophage Migration Inhibitory
Factor Levels in Post-operative Biliary Atresia
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OBJECTIVE: Biliary atresia (BA) is one of the most common causes of neonatal cholestasis. Macrophage
migration inhibitory factor (MIF) is an important mediator of inflammation and immune response in
various diseases. The objective of this study was to examine the possible roles of MIF in BA.
METHODS: Forty-eight BA paediatric patients who had undergone a Kasai operation and 22 healthy
children were recruited. The mean ages of the patients and controls were 8.47 ± 0.74 and 7.64 ± 0.41 years,
respectively. The patients were categorised into two groups according to their serum levels of total biliru-
bin (TB) (TB < 2 mg/dL; no jaundice, and TB ≥ 2 mg/dL; persistent jaundice). The serum MIF levels were
determined using commercially available enzyme-linked immunosorbent assay.
RESULTS: The mean serum MIF level of the BA children was higher than that of healthy controls
(0.43 ± 0.04 pg/mL vs. 0.27 ± 0.02 pg/mL; p < 0.001). However, there was no difference in serum MIF levels
between BA patients with jaundice and those without jaundice. Further analysis revealed that there was
no difference in serum MIF levels of BA patients without portal hypertension compared to that of BA
patients with portal hypertension.
CONCLUSION: MIF production was elevated in BA patients compared to normal controls. It is likely
that MIF plays a role in the pathophysiology of post-operative BA patients. However, the elevated MIF
levels are not associated with either jaundice status or portal hypertension. [Asian J Surg 2009;32(2):109–13]
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Introduction
Biliary atresia (BA) is a progressive obliterative process
involving the extrahepatic and intrahepatic bile ducts in
the newborn. It is characterised by worsening cholestasis,
hepatic fibrosis, and cirrhosis, which lead to portal hyper-
tension and a decline in hepatic synthetic function.1
BA affects approximately 1 in 8,000 to 1 in 15,000 live
births. It is the most common cause of neonatal jaundice
and the prime indication for paediatric liver transplanta-
tion worldwide.2 Approximately 70% to 80% of children
with BA finally require liver transplantation, which is indi-
cated when Kasai portoenterostomy fails and symptoms
of end-stage liver disease appear.3,4 Aetiology and patho-
genesis of BA have remained elusive. No agent has been
confirmed as the cause of this disorder. The variability in
patient presentation and outcome suggests that multiple
factors may play a potential role in BA. A number of 
possible aetiologies of BA include defects due to viral
infection or toxin exposure, defects in morphogenesis,
genetic predisposition, defects in prenatal circulation,
and immune or autoimmune dysregulation.2
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Macrophage migration inhibitory factor (MIF), iden-
tified nearly four decades ago, is considered a pleiotrophic
lymphocyte and macrophage cytokine, but in a number
of reports5 has also been suggested to be an endocrine 
factor. Initially, MIF was reported as an immune response
regulator extracted from the supernatants of T lympho-
cytes and was found to inhibit the random migration of
macrophages. Its activity is associated with macrophage
phagocytosis and delayed-type hypersensitivity.6 Now-
adays, MIF is being cloned7 and its structure has been well
characterised by crystallisation, nuclear magnetic reso-
nance spectroscopy and various biochemical methods.
MIF can be distinguished from other cytokines by a num-
ber of properties. It is expressed in large varieties of tissues
including both immune and non-immune cells. The most
critical functions of MIF are the regulation of macrophage
functions, lymphocyte immunity, and endocrine func-
tions. It plays an important role in the pathogenesis of
several inflammatory diseases, including septic shock,
rheumatoid arthritis, delayed-type hypersensitivity, inflam-
matory lung disease and cancer.8
In addition, MIF also promotes angiogenesis, and 
correlates with cell differentiation. This constitutes a link
to BA based on experimental evidence of a vascular/
ischaemia aetiology for BA as bile ducts receive their
blood supply exclusively from the hepatic arterial circula-
tion; thus, hepatic arterial ischaemia results in bile duct
strictures as observed after liver transplantation.9 Never-
theless, the pathologic role of MIF in BA has not yet been
extensively studied. Recently, associations between MIF
and various liver diseases have been explored in alcoholic
liver disease and chronic hepatitis.10,11 It has been demon-
strated that serum and tissue expression of MIF were
increased in alcoholic liver disease.10 Moreover, serum
MIF levels were elevated and correlated with alanine
aminotransferase in chronic hepatitis. Therefore, serum
MIF levels appear to reflect the severity of tissue injury in
hepatitis B.11
MIF also plays a role in promoting the Th1 immune
response in the development of acute hepatitis and
hepatic injury as demonstrated in hepatitis models in
mice.12 Arikan et al suggested that the −173C allele of the
MIF gene might be associated with susceptibility to BA.13
The present study has been aimed at investigating the
serum MIF levels in BA and to evaluate whether there is
any association between serum MIF and outcome param-
eters in BA patients after Kasai operation.
Materials and methods
This study was approved by the Ethics Committee 
on Human Research of the Faculty of Medicine,
Chulalongkorn University. All parents of children with
BA and of the healthy controls were informed of the
study’s objective. Written informed consent was obtained
from the parents prior to the children’s enrolment into
the study.
Patients
Forty-eight paediatric patients (23 boys and 25 girls; mean
age, 8.47 ± 0.74 years) with BA undergoing Roux-en-Y
hepatic portojejunostomy (original Kasai operation) who
attended the paediatric liver clinic, and 22 healthy chil-
dren (nine boys and 13 girls; mean age, 7.64 ± 0.41 years)
from Anuban-Ratchaburi primary school were enrolled in
the study after acquiring their parents’ written informed
consent. Children in the healthy control group had nor-
mal physical examination results and no underlying dis-
ease. Among the 48 patients with BA, none displayed any
signs or symptoms of fever, ascending cholangitis or clot-
ting abnormalities at the time of blood sampling. None
had received liver transplantation. To compare the various
outcomes among BA patients, according to their levels of
total serum bilirubin (TB) they were categorised into two
groups: patients without jaundice (TB < 2 mg/dL, n = 25)
and patients with persistent jaundice (TB ≥ 2 mg/dL,
n = 23). Based on presence or absence of portal hyperten-
sion (PH), the sample group was categorised into two
groups: patients with PH (n = 26), and patients without
PH (n = 22). PH was validated by the presence of ascities
and/or oesophageal varices on endoscopy.
Laboratory methods
The serum samples were collected and stored at −70°C
until tested. Serum MIF levels were determined by using a
commercially available enzyme-linked immunosorbent
assay (ELISA) kit (Quantikine, R&D System, Minneapolis,
MN, USA) according to the manufacturer’s instructions.
Recombinant human MIF was used to generate the
standard curve. The liver function tests including serum
albumin, total bilirubin, direct bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP), and gamma-glutamyl trans-
peptidase (GGT) were performed using an automated
Hitachi 912 analyser.
■ NATTEE et al ■
110 ASIAN JOURNAL OF SURGERY VOL 32 • NO 2 • APRIL 2009
Statistical analysis
Comparisons of demographic and clinical parameters
between groups were performed using unpaired t-tests. 
A value of p < 0.05 was considered statistically significant.
Data are expressed as mean ± SEM.
Results
MIF concentrations were determined in 48 serum sam-
ples from BA patients and 22 serum samples from healthy
children. No significant difference of age (healthy con-
trols vs. BA patients, 8.47 ± 0.74 years vs. 7.64 ± 0.41 years,
p = 0.16) and gender (male: female, 9:13 vs. 23:25) between
healthy controls and the BA patients was observed.
Comparison between demographic data, liver function
test results, and serum MIF levels between BA patients
without jaundice and BA patients with persistent jaun-
dice is shown in Table.
Serum MIF levels in the entire BA group, jaundice
group, jaundice-free group, and healthy control group
were 0.43 ± 0.04, 0.44 ± 0.06, 0.42 ± 0.04, and 0.27 ± 0.02 pg/
mL, respectively. Serum MIF levels were significantly
higher in BA patients than in the control group (p < 0.001)
as shown in Figure.
BA patients were subsequently re-evaluated according
to total serum bilirubin levels. We found that the differ-
ence in serum levels of MIF was not statistically signifi-
cant between BA patients without jaundice and BA
patients with jaundice (p = 0.8). In addition, serum levels
of MIF were not significantly elevated in BA patients with
PH compared to those without PH (0.43 ± 0.03 pg/mL vs.
0.43 ± 0.04 pg/mL; p = 0.47).
Discussion
Inflammatory cytokines mediate a variety of biological
responses that commonly help augment host immunity,
repair tissue damage and restore cellular and systemic
homeostasis. Although a regulated cytokine response to
pathogens or toxins is essential to host defence and tissue
repair, cytokine excess and imbalance can result in tissue
damage and fibrosis. Macrophage migration inhibitory
factor (MIF) was originally described as the protein secreted
by activated T lymphocytes capable of inhibiting random
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Table. Demographic data, liver function test, and serum MIF levels of the entire BA group, BA patients with jaundice, and patients
without jaundice
BA patients (normal) Total Jaundice Jaundice-free p
No. of patients 48 23 25
Gender (M/F) 23/25 8/15 15/10 NS
Age (yr) 8.47 ± 0.74 6.73 ± 1.07 10.07 ± 0.94 NS
Albumin (3.4–5.5 g/dL) 3.92 ± 0.12 3.46 ± 0.18 4.35 ± 0.09 < 0.001
Total bilirubin (0–1 mg/dL) 5.64 ± 1.07 10.91 ± 1.65 0.80 ± 0.09 < 0.0005
Direct bilirubin (0–0.25 mg/dL) 3.43 ± 0.75 6.90 ± 1.22 0.25 ± 0.05 < 0.0005
AST (0–38 U/L) 144.58 ± 19.80 223.43 ± 32.68 71.84 ± 12.00 < 0.001
ALT (0–38 U/L) 124.19 ± 14.33 173.83 ± 21.28 78.52 ± 15.02 0.001
ALP (39–117 U/L) 491.48 ± 31.07 599.48 ± 36.27 392.12 ± 40.19 < 0.001
GGT (7–50 U/L) 177.67 ± 24.33 252.27 ± 36.82 109.04 ± 26.82 0.003
MIF (pg/mL) 0.43 ± 0.04 0.44 ± 0.06 0.42 ± 0.04 NS
Data are expressed as mean ± SEM. Values of p indicate differences between the jaundice and jaundice-free patients. AST = aspartate amino-
transferase; ALT = alanine aminotransferase; ALP = alkaline phosphatise; GGT = gamma-glutamyl transpeptidase; MIF = migration inhibitory
factor; NS = not significant.
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Figure. Comparison of serum MIF levels between biliary atresia
patients and healthy controls. Data are expressed as mean 
and SEM. *p < 0.001 compared with controls.
migration of macrophages, concentrating macrophages
at inflammation loci, and enhancing their ability to kill
intracellular parasites and tumour cells.14–16 Recent studies
have indicated that other cell types such as macrophages,
endothelial cells, and fibroblasts, can produce MIF,17–19
and various other functions have been attributed to this
molecule, such as the regulation of cell growth, including
tumourigenesis, T cell activation, and angiogenesis.20,21
Recent reports have suggested that MIF plays a criti-
cal role in inflammatory and immune responses. In par-
ticular, MIF has been shown to induce the synthesis of
proinflammatory cytokines, including tumour necrosis
factor-α (TNF-α), interleukin (IL)-1, IL-6, and IL-8 in
immunocompetent cells, and to exert the unique ability
of counteracting the inhibition of cytokine production by
glucocorticoids.22 Moreover, it has recently been verified
that MIF acts as a powerful stimulator for nitric oxide
production.23 Increased serum MIF levels have been
recently documented in several inflammatory diseases
such as rheumatoid arthritis,24 atopic dermatitis,25 glo-
merulonephritis,26 hepatic cirrhosis,11 and alcoholic liver
diseases.10 However, the role of MIF in the pathogenesis
of BA patients has not been fully understood.
Although BA is considered a multi-factorial disorder,
activation of the immune system plays a critical part in 
its development. Recently, a number of inflammatory
cytokines and growth factors have been shown to be ele-
vated in sera of patients with BA including IL-8,27 IL-18,28
hepatocyte growth factor,29 endothelin-130 and connec-
tive tissue growth factor.31 To the best of our knowledge,
no published data are available on serum MIF levels in BA
patients. In the present study, we have investigated for the
first time the circulating levels of MIF in the serum of BA
patients. Significantly higher serum levels of MIF were
observed in BA patients than healthy controls. High
serum MIF levels in BA children suggest that the patho-
genesis of BA might be associated with an inflammatory
process. This evidence is supported by the recent study of
Arikan et al on the positive association of MIF gene-
173G/C polymorphism at the promoter region with BA.13
In the present study hepatic MIF expression has not been
determined. However, it has been shown that the serum
levels of MIF were associated with the intensity of MIF
expression by hepatocytes in patients with hepatocellular
carcinoma and liver cirrhosis.32 Although the liver may 
be a potential source of MIF, other extrahepatic tissues
may be responsible for the increased MIF production in
sera of patients with BA. Other tissues or cells, such as
inflammatory cells and fibroblasts in the liver might also
contribute to MIF production. Another possible explana-
tion may be that higher MIF levels are secondary to
decreased clearance. It might be plausible that increased
MIF levels reflect the hepatocellular damage in BA
patients or that the elevated MIF levels result from an
imbalance between MIF production and MIF clearance.
In conclusion, serum MIF levels were elevated in
patients with BA. It is therefore conceivable that MIF is
involved in the pathophysiology of BA. However, the ele-
vated serum MIF levels are not associated with either
jaundice status or portal hypertension. Further studies
are therefore required in order to fully characterise the
significance of MIF in BA patients.
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